Moderna is raising $2 billion in convertible debt to fund its cancer drug push
The biotech company will sell notes due 2032, with an option to raise an additional $300 million, days after its stock hit a multi-year high
Moderna is set to raise $2 billion through the sale of convertible senior notes due in 2032, according to the company's announcement on Thursday. The funds raised will be utilized for its cancer vaccine business and to repay debt. The Cambridge, Massachusetts-based biotech firm has structured the offering to allow investors the option to purchase up to an additional $300 million in notes.
Following a dramatic 177% surge in Moderna's stock price on August 19, which added $44.5 billion to its market value in a single day, the company is now in a stronger position to negotiate a higher conversion price for the notes. This higher conversion price will result in fewer new shares entering the market, should the notes ultimately be converted, helping to shield existing shareholders from dilution.
It is typical for companies to utilize convertible offerings after a significant rise in their share price, capitalizing on favorable borrowing conditions when investor demand is typically high.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- What’s in Merck and Moderna’s cancer vaccine algorithm? statnews.com
- Moderna raises $2 billion in convertible notes for cancer vaccine finance.yahoo.com
